Pathologists at the Stanford University School of Medicine are trying out a new test from a Sunnyvale company that could give cancer patients a better chance of getting the most effective treatment.
Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...
A business behind AI-driven cancer diagnostic software which is designed to "enhance diagnostic accuracy and speed" has closed its crowdfunding campaign after raising almost £1m. PinPoint's test has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback